Cybrexa Therapeutics
PrivateLast Round
Series B
Mar 10, 2021
Total Funding Raised
$48.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Cybrexa Therapeutics is a biotechnology company that develops oncology therapeutics using its proprietary alphalex platform for antigen-independent intracellular drug delivery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cybrexa Therapeutics Comparables
Compare Cybrexa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| pHLIP, Inc. | 86% | |
| Avacta Group | 83% | |
| AnexAPep Inc. | 79% |
Cybrexa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 10, 2021 | ||||
| Grant | Jul 2, 2019 | ||||
| Series B Extension | Jun 20, 2019 | ||||
| Series B | Jun 6, 2017 |
Cybrexa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| China Capital | Series B |
| National Cancer Institute | Grant |
| Connecticut Innovations | Series B Extension, Series B |
| HighCape Capital | Series B, Series B Extension |
| NIH RADx | Grant |
| Elm Street Ventures | Series B |
| Cycle Capital | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 100% MoM, reaching 1.2K.
- Mar 5, 2025
Presented data at the ESMO 2025 conference.
Cybrexa Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cybrexa Therapeutics's valuation, stock price, and market status.
Is Cybrexa Therapeutics a public or private company?
Cybrexa Therapeutics is a private company.
What is the current stock price of Cybrexa Therapeutics?
Cybrexa Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Cybrexa Therapeutics worth (valuation)?
Valuation information for Cybrexa Therapeutics is not publicly available.
Can I buy Cybrexa Therapeutics stock?
Cybrexa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Cybrexa Therapeutics's last funding round?
Cybrexa Therapeutics's most recent funding round was Series B on March 10, 2021.
Who are the main investors in Cybrexa Therapeutics?
Key investors in Cybrexa Therapeutics include Cycle Capital.
Will Cybrexa Therapeutics IPO soon?
No public IPO plans have been announced for Cybrexa Therapeutics.
How can I track Cybrexa Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cybrexa Therapeutics's secondary market activity and sign up for updates.